Results for tag: "Fuchs Dystrophy Drug"

The Fuchs Dystrophy Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Fuchs Dystrophy is a rare, progressive eye disorder that affects the cornea, the clear outer layer of the eye. It is caused by a buildup of fluid in the cornea, leading to swelling and clouding of the cornea. Treatment for Fuchs Dystrophy includes medications, such as corticosteroids, and surgical procedures, such as corneal transplantation. The Fuchs Dystrophy Drug market is composed of pharmaceutical companies that develop and market drugs to treat Fuchs Dystrophy. These drugs are typically used to reduce inflammation and swelling of the cornea, as well as to improve vision. The market is highly competitive, with many companies vying for market share. Some of the major players in the Fuchs Dystrophy Drug market include Allergan, Bausch + Lomb, Santen Pharmaceuticals, and Shire. These companies are actively developing and marketing drugs to treat Fuchs Dystrophy, and are competing for market share. Show Less Read more